Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,782 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06449989Recruiting
Comparing genetics of colorectal cancer and its brain spread
This study compares the genetics of the original colorectal cancer with the cancer that has spread to the brain. It aims to understand how the tumor changes when it metastasizes, which may help guide future treatments.
Moscow, MoscowAges 18 years+ - NCT06479239RecruitingPhase 1/Phase 2
Immune cell therapy for advanced pancreatic cancer
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Charlottesville, VirginiaAges 18 years+ - NCT06481813Recruiting
Lung Cancer Biobank Study for Newly Diagnosed Patients
This trial collects blood and tissue samples from people newly diagnosed with lung cancer (NSCLC or CPC) to study the disease over time. It helps researchers understand how different treatments affect the cancer and the body.
NantesAges 18 years+ - NCT07691697Recruiting
PSMA PET-guided radiation for slowing prostate cancer growth
This trial uses a special scan called PSMA PET to find and treat a small number of cancer spots that are growing while you are on standard treatment. The goal is to give precise radiation to those spots to help keep the rest of the cancer under control.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Calverton, MarylandAges 18 years+ - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06509126RecruitingPhase 3
Panitumumab with Chemo: Continuous or Intermittent for Advanced CRC
This trial compares giving panitumumab plus FOLFIRI (two chemotherapy drugs) either continuously or with breaks, as a first treatment for left-sided colorectal cancer that has spread. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and haven't had treatments for advanced disease before.
NaplesAges 18–100 - NCT06522828RecruitingPhase 2
Study of SSGJ-707 for advanced gynecologic cancers
This trial tests a new drug called SSGJ-707 for people with advanced endometrial cancer or ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it can help shrink or slow down the cancer.
ChongqingAges 18–75 - NCT06524570RecruitingPhase 1
Focused ultrasound plus immune therapy for advanced cancer
This trial tests a new treatment that combines a special type of focused ultrasound (called histotripsy) with an immune checkpoint inhibitor to boost the immune system's attack on cancer. It is for people with advanced cancer that has not responded to standard treatments.
Utrecht, UtrechtAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT06601296RecruitingPhase 2
Radiation plus immunotherapy for metastatic kidney cancer
This trial tests whether combining radiation therapy with two types of immunotherapy (checkpoint inhibitors and an injectable drug called IMSA101) can help control metastatic kidney cancer that is only growing in a few spots. The goal is to see if this approach can shrink tumors and keep them from growing further.
Dallas, TexasAges 18 years+ - NCT06610825RecruitingPhase 2
Enhertu for prostate cancer resistant to hormone therapy
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06627244RecruitingPhase 2
Study of tebentafusp and radioembolization for uveal melanoma that spread to the liver
This trial tests whether combining a drug called tebentafusp with a procedure called radioembolization can help control uveal melanoma that has spread mainly to the liver. Radioembolization delivers tiny radioactive beads to the liver, and tebentafusp helps your immune system attack the cancer.
Miami, FloridaAges 18 years+ - NCT06642857Recruiting
Predicting treatment response for advanced stomach cancer
This trial uses advanced testing to predict how well stomach cancer responds to chemotherapy combined with immunotherapy. It may help find the best treatment for advanced or metastatic stomach or gastroesophageal junction cancer that hasn't been treated yet.
Hangzhou, ZhejiangAges 18–75 - NCT06665178RecruitingPhase 2
Testing SG after T-DXd in ER+/HER2-low metastatic breast cancer
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
Vancouver, British ColumbiaAges 18 years+ - NCT06675357RecruitingPhase 2
FAPI PET/MRI scan for prostate cancer
This trial uses a new type of PET/MRI scan (called FAPI) to see how well it can find prostate cancer. It may help doctors learn about a different way to image the cancer. You can join if you already have a scheduled or recent PSMA PET scan.
Madison, WisconsinAges 18 years+ - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT04968964Recruiting
Monitoring test for CDK4/6 drugs in metastatic breast cancer
This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.
St Louis, MissouriAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT06713161Recruiting
New dye to spot breast cancer during surgery
This study tests a special dye that helps surgeons see breast cancer tissue and nearby lymph nodes more clearly during surgery. The goal is to make sure all cancer is removed while sparing healthy tissue.
Kunming, YunnanAges 18–75 - NCT06714357RecruitingPhase 2
Valproic Acid to Boost Anti-EGFR in Colorectal Cancer
This trial tests whether adding valproic acid to standard anti-EGFR plus irinotecan can stop or reverse resistance in metastatic colorectal cancer. It is for patients who previously responded well to an anti-EGFR drug and then progressed.
Caserta, CEAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,782 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.